## Management of Breakthrough Bleeding in Early COC Use **Key Point:** Breakthrough bleeding (BTB) in the first 1–3 months of COC use is common and usually self-limited due to endometrial thinning and adaptation. It does NOT require immediate pill switching in the absence of other contraindications. ### Why Continuation Is the Right Approach Breakthrough bleeding occurs in approximately 10–30% of users during the first 3 months of COC initiation. The endometrium undergoes remodeling and stabilization over this period. Most cases resolve spontaneously by cycle 3–4 without intervention. **Clinical Pearl:** Minor side effects such as BTB and breast tenderness in the first trimester of COC use are expected and often improve with continued use. Patient reassurance and adherence counselling are key. ### When to Switch Formulations Switch to a higher-dose estrogen or different progestin only if: - BTB persists beyond 3 months of consistent use - Patient compliance is confirmed (no missed pills) - Other causes (infection, polyps, fibroids) have been excluded - Patient is distressed and counselling has failed ### Why Higher-Dose Estrogen Is Not First-Line Increasing estrogen dose increases thrombotic and cardiovascular risk, especially in women over 35 or smokers. Modern practice favors the lowest effective dose. A 30 µg formulation is standard-of-care and should be continued unless BTB persists beyond 3 months. **High-Yield:** The "rule of 3 months" — most COC side effects settle by the third cycle without intervention. ### Breast Tenderness Breast tenderness is also a common early side effect and typically resolves within 1–2 months. It is not a reason to discontinue the pill unless severe. **Mnemonic: ADAPT** — Allow time, Discontinue only if persistent, Assess compliance, Provide reassurance, Track at follow-up.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.